CN108794588A - A kind of biologically active polypeptide FDPTLHQ and its preparation method and application - Google Patents
A kind of biologically active polypeptide FDPTLHQ and its preparation method and application Download PDFInfo
- Publication number
- CN108794588A CN108794588A CN201810711974.9A CN201810711974A CN108794588A CN 108794588 A CN108794588 A CN 108794588A CN 201810711974 A CN201810711974 A CN 201810711974A CN 108794588 A CN108794588 A CN 108794588A
- Authority
- CN
- China
- Prior art keywords
- fdptlhq
- biologically active
- active polypeptide
- polypeptide
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 126
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 101
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 230000003005 anti-senility effect Effects 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 230000003712 anti-aging effect Effects 0.000 claims description 9
- 230000032050 esterification Effects 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- 230000000640 hydroxylating effect Effects 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000026731 phosphorylation Effects 0.000 claims description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 4
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 4
- 230000021736 acetylation Effects 0.000 claims description 4
- 238000006640 acetylation reaction Methods 0.000 claims description 4
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 3
- 241000005787 Cistanche Species 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 125000003147 glycosyl group Chemical group 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 24
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 14
- 210000002540 macrophage Anatomy 0.000 abstract description 13
- 230000032683 aging Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 230000001939 inductive effect Effects 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 230000003035 anti-peroxidant effect Effects 0.000 abstract description 2
- 230000036259 sexual stimuli Effects 0.000 abstract 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 58
- 239000011347 resin Substances 0.000 description 20
- 229920005989 resin Polymers 0.000 description 20
- 238000005516 engineering process Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000035611 feeding Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241000255601 Drosophila melanogaster Species 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 150000003053 piperidines Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 108010009298 lysylglutamic acid Proteins 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- -1 aromatic amino acid Chemical class 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KHBLRHKVXICFMY-GUBZILKMSA-N Asp-Glu-Lys Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O KHBLRHKVXICFMY-GUBZILKMSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 2
- CUTSCJHLMGPBEJ-UHFFFAOYSA-N [N].CN(C)C=O Chemical compound [N].CN(C)C=O CUTSCJHLMGPBEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- ZQOILFFBJUNGRA-NMVUUJPQSA-N (4s)-4-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-[(2s)-2-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C ZQOILFFBJUNGRA-NMVUUJPQSA-N 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- SDZRIBWEVVRDQI-CIUDSAMLSA-N Ala-Lys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O SDZRIBWEVVRDQI-CIUDSAMLSA-N 0.000 description 1
- XVVOVPFMILMHPX-ZLUOBGJFSA-N Asn-Asp-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XVVOVPFMILMHPX-ZLUOBGJFSA-N 0.000 description 1
- VBVKSAFJPVXMFJ-CIUDSAMLSA-N Asp-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N VBVKSAFJPVXMFJ-CIUDSAMLSA-N 0.000 description 1
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 1
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700002304 Drosophila can Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- OETQLUYCMBARHJ-CIUDSAMLSA-N Gln-Asn-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OETQLUYCMBARHJ-CIUDSAMLSA-N 0.000 description 1
- KWLMLNHADZIJIS-CIUDSAMLSA-N Gln-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)N KWLMLNHADZIJIS-CIUDSAMLSA-N 0.000 description 1
- PSERKXGRRADTKA-MNXVOIDGSA-N Gln-Leu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PSERKXGRRADTKA-MNXVOIDGSA-N 0.000 description 1
- TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 description 1
- SXGMGNZEHFORAV-IUCAKERBSA-N Gln-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXGMGNZEHFORAV-IUCAKERBSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- ZWABFSSWTSAMQN-KBIXCLLPSA-N Glu-Ile-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O ZWABFSSWTSAMQN-KBIXCLLPSA-N 0.000 description 1
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 1
- COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UPGJWSUYENXOPV-HGNGGELXSA-N His-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N UPGJWSUYENXOPV-HGNGGELXSA-N 0.000 description 1
- DRKZDEFADVYTLU-AVGNSLFASA-N His-Val-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O DRKZDEFADVYTLU-AVGNSLFASA-N 0.000 description 1
- PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 1
- IBQMEXQYZMVIFU-SRVKXCTJSA-N Lys-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N IBQMEXQYZMVIFU-SRVKXCTJSA-N 0.000 description 1
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 1
- QQPMHUCGDRJFQK-RHYQMDGZSA-N Met-Thr-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QQPMHUCGDRJFQK-RHYQMDGZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- MQVFHOPCKNTHGT-MELADBBJSA-N Phe-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O MQVFHOPCKNTHGT-MELADBBJSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- FNGOXVQBBCMFKV-CIUDSAMLSA-N Pro-Ser-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O FNGOXVQBBCMFKV-CIUDSAMLSA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 1
- XIULAFZYEKSGAJ-IXOXFDKPSA-N Thr-Leu-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XIULAFZYEKSGAJ-IXOXFDKPSA-N 0.000 description 1
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FJKXUIJOMUWCDD-FHWLQOOXSA-N Tyr-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N)O FJKXUIJOMUWCDD-FHWLQOOXSA-N 0.000 description 1
- ZRPLVTZTKPPSBT-AVGNSLFASA-N Tyr-Glu-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZRPLVTZTKPPSBT-AVGNSLFASA-N 0.000 description 1
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 1
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 1
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 1
- NYTKXWLZSNRILS-IFFSRLJSSA-N Val-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N)O NYTKXWLZSNRILS-IFFSRLJSSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 108010030651 valyl-glutamyl-prolyl-isoleucyl-prolyl-tyrosine Proteins 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to albumen fields, and in particular to its amino acid sequence of a kind of biologically active polypeptide FDPTLHQ and its preparation method and application, biologically active polypeptide FDPTLHQ is Phe-Asp-Pro-Thr-Leu-His-Gln.By extracorporeal anti-inflammatory activity experiment, internal Antisenility Experiment, demonstrating polypeptide FDPTLHQ has preferable anti-inflammatory activity and activity of fighting against senium, on the one hand, the biologically active polypeptide FDPTLHQ of the present invention can promote Factor of Macrophage, promote the increase of the macrophage nitric oxide amount of inducing, the ability that body resists extraneous pathogenic infection is improved, body incidence is reduced；On the other hand, the vigor of internal anti-peroxidation enzyme system can be improved, enhance the function that body resists external source sexual stimulus, to reduce organism aging process, aging and sick probability, there is anti-inflammatory properties, the food of anti-senescence function, health products and drug to have a very important significance exploitation.
Description
Technical field
The present invention relates to albumen fields, more particularly, to a kind of biologically active polypeptide FDPTLHQ and preparation method thereof and answer
With.
Background technology
During cow's milk is through lactobacillus-fermented, a part of protein in cow's milk is metabolized by lactic acid bacteria to be utilized, concurrently
A series of biochemical reactions have been given birth to, so that protein is become polypeptide or free amino acid, is digested or passes through
The absorption and transport of intestinal epithelial cell is directly entered the blood circulation of human body.There is also the eggs of some itself synthesis for lactic acid bacteria thalline
White matter polypeptide fragment is utilized for bacterial growth.In these polypeptides, some is referred to as " raw with special physiological function
Object active peptide ".
It is particularly important that safe biologically active peptide is found in natural food source.In recent years, it has been found that some foods
The polypeptides matter in object source has good bioactivity, such as corn small peptide, soybean peptide, cow's milk polypeptide.These polypeptides can
To be obtained by number of ways such as microbial fermentation, digestion enzymolysis, and biologically active polypeptide is by 2~20 mostly
Amino acid residue forms, and molecular weight is less than 6000Da, contains a certain amount of hydrophobic amino acid, aromatic amino acid.
Immune-active peptides are to obtain and prove that one kind biology of its physiological activity is living from breast for the first time after opioid peptides discovery
Property polypeptide.Jolles in 1981 et al. has found for the first time, using trypsin hydrolysis people lactoprotein, can obtain an amino acid sequence
It is classified as the hexapeptide of Val-Glu-Pro-Ile-Pro-Tyr, experiment in vitro proves that the peptide can enhance Turnover of Mouse Peritoneal Macrophages pair
The phagocytosis of sheep red blood cell (SRBC).Migliore-Samour et al. has found the hexapeptide Thr-Thr-Met-Pro- from casein
Leu-Trp can stimulate sheep erythrocyte to the phagocytosis of mouse peritoneal macrophages and enhancing for kerekou pneumonia primary
The resistance of bacterium has anti-inflammatory properties.Newborn source peptide (PGPIPN) the feeding rat of Li Su duckweeds et al. synthesis finds that rat abdominal cavity is huge
The phagocytosis of phagocyte and the relevant anti-inflammatory properties of red blood cell have significant enhancing.
Studies have shown that immune-active peptides can not only enhance immunity of organisms, the proliferation of body lymphocyte, enhancing are stimulated
The phagocytic function of macrophage promotes the release of cell factor, the increase for promoting the macrophage nitric oxide amount of inducing, raising machine
Body resists the ability of extraneous pathogenic infection, reduces body incidence, and will not cause the immunological rejection of body.
Aging is a natural phenomena, and process is often accompanied by the variation of antioxidant levels, organ-tissue, immune factor,
Complicated variation occurs for middle cell factor, such as the trend that proinflammatory cytokine IL-6, IL-4, TNF-α presentation increase, IL-6
It is all considered to play an important role in the generating process of geriatric disease with TNF-a.With science of heredity and molecular biology
Development, the research of biological decay mechanism achieve gratifying progress.Researcher by using some model organisms, as mouse,
The term single gene mutating experiment of drosophila and caenorhabditis elegan etc. finds that some genes can dramatically increase service life of these organisms and reach
As many as 6 times.
Anti-aging peptide as a kind of emerging antidotal agent, in terms of physiological function have amino acid cannot compare it is excellent
Gesture can generate promotion or inhibiting effect to the enzyme in organism, improve the absorption to minerals and other nutrients and profit
With removing interior free yl enhances the resistance to oxidation of body itself, to slow down aging.Therefore, the nutrition and health care of biologically active peptide
Effect has become the emphasis of domestic and foreign scholars' subject study.Qiu Juan et al. pass through experimental studies have found that, milk-derived bioactive micro peptide
Life span of drosophila melanogaster can effectively be extended, delay its aging, and also there is preferable antioxidation, thus it is speculated that may be wherein to be rich in coloured glaze
Base peptides.SOD vigor in serum, reduces its lipid in discovery bovine colostrum extract energy conspicuousness raising the elderly's body such as the brightness in week
Peroxide and enhancing body resistance to oxidation, have certain anti-senescence function.
Have much about the research of biologically active polypeptide at present, for example Chinese patent CN105254738A discloses one kind and comes
Derived from the milk-derived biologically active polypeptide DELQDKIH of beta-casein, Chinese patent CN105254739A discloses one kind and derives from
Milk-derived the biologically active polypeptide GTQYTD, Chinese patent CN105254740A of α s1- caseins disclose a kind of from α s2-
The milk-derived biologically active polypeptide NQFYQKF of casein.
Invention content
The purpose of the present invention is to provide a kind of biologically active polypeptide FDPTLHQ and its preparation method and application.
The purpose of the present invention can be achieved through the following technical solutions：
First aspect present invention provides a kind of biologically active polypeptide FDPTLHQ, amino acid sequence Phe-Asp-Pro-
Thr-Leu-His-Gln, such as SEQ ID NO：Shown in 1.
Preferably, the biologically active polypeptide derives from Lactobacillus helveticus mycoprotein.It is derive specifically from LBH_1099 |
m.1026 LBH_1099|g.1026 ORF LBH_1099|g.1026 LBH_1099|m.1026 type:5prime_
partial len:206(+)LBH_1099:1-618 (+) albumen, and the amino acid residue of the 159th~165, albumen thus.
LBH_1099|m.1026 LBH_1099|g.1026 ORF LBH_1099|g.1026 LBH_1099|m.1026type:
5prime_partial len:206(+)LBH_1099:1-618 (+) protein amino acid sequence such as SEQ ID NO：Shown in 3.
LBH_1099|m.1026 LBH_1099|g.1026 ORF LBH_1099|g.1026 LBH_1099|
m.1026type:5prime_partial len:206(+)LBH_1099:The amino acid sequence and correspondence of 1-618 (+) albumen
Nucleotides sequence be classified as existing technology, encode the nucleotide fragments energy encoding mature of this 159th~165 amino acids residue of albumen
Biologically active polypeptide FDPTLHQ.
Preferably, the biologically active polypeptide has anti-inflammatory properties and anti-senescence function.
Second aspect of the present invention provides the nucleotide fragments for encoding the biologically active polypeptide FDPTLHQ, sequence
For：5 '-att tga tcc gac att gca tca-3 ', such as SEQ ID NO：Shown in 2.
Third aspect present invention provides the preparation method of the biologically active polypeptide FDPTLHQ, can pass through gene work
The method of journey is artificial synthesized, can be directly obtained from Lactobacillus helveticus thalline by the method that clasmatosis isolates and purifies, can be with
Directly prepared by chemical synthesis.
Fourth aspect present invention, provide the biologically active polypeptide FDPTLHQ prepare with anti-inflammatory properties food,
Application in health products, drug or cosmetics.
Fifth aspect present invention provides the biologically active polypeptide FDPTLHQ and is preparing the food with anti-senescence function
Application in product, health products or drug.
Sixth aspect present invention, provide the biologically active polypeptide FDPTLHQ prepare and meanwhile have anti-inflammatory properties with
Application in the food of anti-senescence function, health products or drug.
Specifically, the biologically active polypeptide FDPTLHQ of the present invention, which can be used for preparing, reduces free radical to skin damage
Cosmetics, prepare have anti-inflammatory and/or anti-aging drug；And since the biologically active polypeptide FDPTLHQ of the present invention is logical
The product crossed after gastrointestinal tract degradation still has bioactivity, therefore can be also used for preparing the food such as Yoghourt, adjusts immunity
Health products, and oral be used to prepare with anti-inflammatory and/or anti-aging drug.
Seventh aspect present invention provides a kind of anti-inflammatory products, including the biologically active polypeptide FDPTLHQ or described lifes
The derivative of object active peptides FDPTLHQ；The anti-inflammatory products include anti-inflammatory food, anti-inflammatory health product, anti-inflammatory drug or anti-
Scorching cosmetics；The derivative of the biologically active polypeptide FDPTLHQ refers in the amino acid side of biologically active polypeptide FDPTLHQ
On chain group, aminoterminal or c-terminus carry out hydroxylating, carboxylated, be carbonylated, methylate, acetylation, phosphorylation, esterification or sugar
The modifications such as base, obtained polypeptide derivative.
Eighth aspect present invention provides a kind of anti-aging product, including the biologically active polypeptide FDPTLHQ or described
The derivative of biologically active polypeptide FDPTLHQ；The anti-aging product includes antisenility cistanche food, antisenescence health product or anti-ageing
Old drug；The derivative of the biologically active polypeptide FDPTLHQ refers to the amino acid side chain in biologically active polypeptide FDPTLHQ
On group, aminoterminal or c-terminus carry out hydroxylating, carboxylated, be carbonylated, methylate, acetylation, phosphorylation, esterification or glycosyl
The modifications such as change, obtained polypeptide derivative.
Ninth aspect present invention provides product that is a kind of while having anti-inflammatory properties and anti-senescence function, including described
The derivative of biologically active polypeptide FDPTLHQ or described biologically active polypeptides FDPTLHQ；With anti-inflammatory properties and anti-senescence function
Product include food, health products or drug；The derivative of the biologically active polypeptide FDPTLHQ refers to more in bioactivity
On the amino acid side groups of peptide FDPTLHQ, aminoterminal or c-terminus progress hydroxylating, carboxylated, it is carbonylated, methylates, second
The modifications such as acylation, phosphorylation, esterification or glycosylation, obtained polypeptide derivative.
Biologically active polypeptide FDPTLHQ's of the present invention has the beneficial effect that：The biologically active polypeptide FDPTLHQ of the present invention has
Preferable anti-inflammatory activity and activity of fighting against senium；On the one hand, biologically active polypeptide FDPTLHQ of the invention can promote macrophage
Secrete cytokines promote the increase of the macrophage nitric oxide amount of inducing, and improve the energy that body resists extraneous pathogenic infection
Power reduces body incidence；On the other hand, the vigor of internal anti-peroxidation enzyme system can be improved, enhancing body is resisted exogenous
The function of stimulation, to reducing organism aging process, aging and sick probability, to developing with anti-inflammatory properties, anti-senescence function
Food, health products and drug have a very important significance.
Description of the drawings
Fig. 1：Mass chromatography extraction figure (m/z=857.4269)；
Fig. 2：The second order ms figure for the segment that mass-to-charge ratio is 857.4269；
Fig. 3：Polypeptide az, by crack conditions that mass-to-charge ratio is 857.4269；
Fig. 4：Influence situations of the biologically active polypeptide FDPTLHQ to drosophila survival rate；
Fig. 5：Hydrogen peroxide (H2O2) acute experiment.
Specific implementation mode
Before further describing specific embodiments of the present invention, it should be appreciated that protection scope of the present invention is not limited to down
State specific specific embodiment；It is also understood that the term used in the embodiment of the present invention is specific specific in order to describe
Embodiment, the protection domain being not intended to be limiting of the invention.
When embodiment provides numberical range, it should be appreciated that except non-present invention is otherwise noted, two ends of each numberical range
Any one numerical value can be selected between point and two endpoints.Unless otherwise defined, in the present invention all technologies for using and
Scientific terminology is identical as the normally understood meaning of those skilled in the art of the present technique.Except used in embodiment specific method, equipment,
Outside material, the record according to those skilled in the art to the grasp of the prior art and the present invention can also use and this
Any method, equipment and the material of the similar or equivalent prior art of method, equipment described in inventive embodiments, material come real
The existing present invention.
Unless otherwise stated, disclosed in this invention experimental method, detection method, preparation method be all made of this technology neck
Molecular biology, biochemistry, chromatin Structure and the analysis of domain routine, analytical chemistry, cell culture, recombinant DNA technology and
The routine techniques of related field.These technologies existing perfect explanation in the prior art, for details, reference can be made to Sambrook etc.
MOLECULAR CLONING：A LABORATORY MANUAL, Second edition, Cold Spring Harbor
Laboratory Press, 1989and Third edition, 2001；Ausubel etc., CURRENT PROTOCOLS IN
MOLECULAR BIOLOGY, John Wiley&Sons, New York, 1987and periodic updates；the
Series METHODS IN ENZYMOLOGY, Academic Press, San Diego；Wolffe, CHROMATIN
STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998；METHODS IN
ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), Academic
Press, San Diego, 1999；With METHODS IN MOLECULAR BIOLOGY, Vol.119, Chromatin
Protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc..
The present invention is described in detail with specific embodiment below in conjunction with the accompanying drawings.
1 active peptide FDPTLHQ's of embodiment is artificial synthesized
One, the synthesis of biologically active peptide
1. RINK resin 3g (degree of substitution 0.3mmol/g) are weighed in the reactor of 150ml, with the dichloromethane of 50ml
(DCM) it impregnates.
After 2.2 hours, resin is washed with nitrogen-dimethylformamide (DMF) of 3 times of resin volumes, is then drained, so weight
It is four times multiple, it is for use after resin is drained.
3. a certain amount of 20% piperidines (piperidines/DMF=1 is added into reactor:4,v:V), it is placed on decolorization swinging table and shakes
20min is shaken, the Fmoc blocking groups on resin are sloughed with this.It is washed four times with the DMF of 3 times of resin volumes after having taken off protection,
Then it drains.
4. taking the detection of a small amount of resin ninhydrin (nine well ninhydrins) method (each two drop of inspection A, inspection B, 100 DEG C of reactions
1min), resin has color, illustrates to be deprotected successfully.
5. it weighs amino acid Phe in right amount and 1- hydroxyls-benzene a pair of horses going side by side triazole (HOBT) is in right amount in the centrifuge tube of 50ml, addition
The DMF of 20ml is dissolved, and the N of 3ml is then added, and N diisopropylcarbodiimide (DIC) oscillation shakes up 1min, waits for that solution is clear
It is added in reactor after clear, then reactor is placed in 30 DEG C of shaking table and is reacted.
After 6.2 hours, with a certain amount of acetic anhydride end socket (acetic anhydride:DIEA:DCM=1:1:2,v:v:V) half an hour, so
It is washed four times, is drained for use with the DMF of 3 times of resin volumes afterwards.
7. a certain amount of 20% piperidines (piperidines/DMF=1 is added into reactor:4, v:V), it is placed on decolorization swinging table and shakes
20min is shaken, the Fmoc blocking groups on resin are sloughed with this.It is washed four times with DMF after having taken off protection, is then drained.
8. taking the detection of a small amount of resin ninhydrin (nine well ninhydrins) method (each two drop of inspection A, inspection B, 100 DEG C of reactions
1min), resin has color, illustrates to be deprotected successfully.
9. weighing second amino acid next in right amount and HOBT being in right amount in the centrifuge tube of 50ml, the DMF generals of 25ml are added
It is dissolved, and the DIC oscillations that 2.5ml is then added shake up 1min, are added in reactor after solution clarification, then by reactor
It is placed in 30 DEG C of shaking table and reacts.
After 10.1 hours, a small amount of resin is taken to detect, with ninhydrin method detection (each two drop of inspection A, inspection B, 100 DEG C of reactions
1min), if resin is colourless, illustrate that the reaction was complete；If resin has color, illustrate that condensation is incomplete, the reaction was continued.
11. after complete reaction, washing resin four times with DMF, then drains, a certain amount of 20% is added into reactor
Piperidines (piperidines/DMF=1:4,v:V), it is placed on decolorization swinging table and rocks 20min, the Fmoc protecting groups on resin are sloughed with this
Group.It is washed four times with DMF after having taken off protection, then drains whether detection protection sloughs.
12. connecting amino acid Asp, Pro, Thr, Leu, His and Gln successively according to step 9-11.
13. after connecting the last one amino acid, protection is sloughed, is washed four times with DMF, is then taken out resin with methanol
It is dry.Then with 95 cutting liquid (trifluoroacetic acids:1,2 dithioglycols:3, isopropyl base silane:Water=95:2:2:1, v:v:V) by polypeptide
(every gram of resin adds 10ml cutting liquids) is cut down from resin, and ice ether (cutting liquid is used in combination：Ether=1:9,v:V) centrifugation is heavy
Drop four times.
So far, artificial synthesized biologically active peptide FDPTLHQ.
Two, the confirmation of biologically active peptide
1) UPLC is analyzed
UPLC conditions are as follows：
Instrument：Waters ACQUITY UPLC ultra high efficiencies liquid phase-electron spray-level four bars-time of-flight mass spectrometer
Chromatographic column specification：BEH C18 chromatographic columns
Flow velocity：0.4mL/min
Temperature：50℃
Ultraviolet detection wavelength：210nm
Sample size：2μL
Gradient condition：A liquid：Water containing 0.1% formic acid (v/v), B liquid：Acetonitrile containing 0.1% formic acid (v/v)
2) mass spectral analysis
Mass Spectrometry Conditions are as follows：
Ionic means：ES+
Mass range (m/z)：100-1000
Capillary voltage (Capillary) (kV)：3.0
Sampling spiroid (V)：35.0
Ion source temperature (DEG C)：115
Remove solvent temperature (DEG C)：350
Go solvent stream (L/hr)：700.0
Collision energy (eV)：4.0
Sweep time (sec)：0.25
Interior sweep time (sec)：0.02
According to the above analysis method, using ultra high efficiency liquid phase-electron spray-level four bars-flight time mass spectrum, to bioactivity
Peptide FDPTLHQ carries out chromatography and mass spectral analysis, and mass chromatography extraction figure is as shown in Figure 1, extract the second order ms at this peak
Figure and az, by crack conditions are as shown in Figures 2 and 3, and the polypeptide mass-to-charge ratio that can obtain this peak is 857.4269Da, and retention time is
42.1min。
3) result
From the figure 3, it may be seen that the case where being broken according to az, by, analyzes by Mascot softwares and calculates, obtain mass-to-charge ratio
The fragment sequence of 857.4269Da is Phe-Asp-Pro-Thr-Leu-His-Gln (FDPTLHQ), is denoted as SEQ ID NO：1.It should
Segment and LBH_1099 | m.1026 LBH_1099 | g.1026 ORF LBH_1099 | g.1026 LBH_1099 | m.1026
type:5prime_partial len:206(+)LBH_1099:The residue sequence of the 159th~165,1-618 (+) albumen is opposite
It answers, sequence is shown in SEQ ID NO：3.
The anti-inflammatory activity of 2 biologically active peptide of embodiment is tested
One, the experiment (ELISA method) of the rush Factor of Macrophage of biologically active polypeptide FDPTLHQ
1. experiment reagent and instrument：
Reagent：Experimental animal balb/c mouse (male 6-8 week old), Shanghai Slac Experimental Animal Co., Ltd.；Mouse
Lymphocyte extracting solution, the Shanghai bio tech ltd Suo Laibao；RPMI1640 culture mediums, GIBCO companies；Bovine serum albumin
(bovine serum albumin, BSA) in vain, Genebase companies；The biologically active polypeptide FDPTLHQ that embodiment 1 obtains；
ELISA cell factors Quick kit (TNF-α, IL-1 β and IL-6), Wuhan Boster Biological Technology Co., Ltd..
Instrument and equipment：LRH-250F biochemical cultivation cases Shanghai perseverance Science and Technology Ltd.；On GL-22M high speed freezing centrifuges
Hai Luxiang instrument centrifuges Instrument Ltd.；Hera cell 150CO2 incubator Heraeus companies；Dragon Wellscan
MK3 microplate reader Labsystems companies.
2. experimental method：
It is 2 × 10 that number of cells, which is added,6100 holes μ l/ of cell suspension of/ml, it is adherent to be added after purification containing peptide
LPS to 10 μ g/ml of final concentration was added at 24 hours for 200 holes μ l/ of RPMI1640 complete culture solutions (10%FBS), inflammation group, even
Continuous culture 48 hours, inflammation group terminate first 24 hours in culture and LPS to final concentration 100ng/ml are added.After culture terminates, centrifugation
Collect cell culture supernatant liquid.100 μ l supernatants, 37 DEG C of reactions 90 are added in the ELISA Plate of coated cell factor antibody
After minute, biotin labelled antibodies are added, 37 DEG C are reacted 60 minutes, and after PBS washings, it is compound that Avidin-peroxidase is added
Object reacts 30 minutes.Developing solution is added after PBS washings, reacts 20 minutes.After colour developing terminate liquid is added, using microplate reader in wave
Absorbance value (OD450) is measured under long 450nm.
3. experimental result and analysis：
The measurement that 1 biologically active peptide FDPTLHQ of table influences Macrophage Cell factor level
Note：*, compared with negative control, significant difference (P < 0.05)；* has significantly compared with negative control group
Sex differernce (P < 0.01)
As can be known from Table 1, in TNF-α, the experimental result of IL-1 β and IL-6 these three cell factors, TNF-α, IL-1 β
In 0.2mg/ml and significant difference (P < 0.01) is appeared above, IL-6 significant difference (P < occurs in 0.5mg/ml
0.01), it was demonstrated that the FDPTLHQ under a certain concentration can promote the Turnover of Mouse Peritoneal Macrophages to activate and discharge TNF-α, IL-1 β,
IL-6 improves floors of these cell factors under normal macrophages quiescent condition, to adjust the immunity of body.
Two, the measurement (Griess methods) of the rush macrophage nitric oxide amount of inducing of biologically active polypeptide FDPTLHQ
1. experiment reagent and instrument：
Reagent：Experimental animal balb/c mouse (male 6-8 week old) Shanghai Communications University's agricultural and biological institute animal reality
Test center；The biologically active polypeptide FDPTLHQ that embodiment 1 obtains；LPS is purchased from Sigma companies；Neutral red staining solution, the green skies
Biotechnology research institute produces.
Instrument and equipment：LRH-250F biochemical cultivation cases Shanghai perseverance Science and Technology Ltd.；On GL-22M high speed freezing centrifuges
Hai Luxiang instrument centrifuges Instrument Ltd.；Hera cell 150CO2 incubator Heraeus companies；Dragon Wellscan
MK3 microplate reader Labsystems companies.
2. test method：
It is 2 × 10 that number of cells, which is added,6100 holes μ l/ of cell suspension of/ml, it is adherent to be added after purification containing peptide
LPS is added to 10 μ g/ml of final concentration, continuously in 200 holes μ l/ of RPMI1640 complete culture solutions (10%FBS), inflammation group when for 24 hours
After cultivating 48h, 50 holes μ l/ of culture solution supernatant are collected, add Griess reagents 1 and Griess reagents successively in culture solution supernatant
2 each holes 50 μ l/, room temperature reaction after ten minutes, measure absorbance value (OD540) under 540nm wavelength.
3. experimental result and analysis：
2 biologically active polypeptide FDPTLHQ of table promotees the measurement of the macrophage nitric oxide amount of inducing
Note：*, compared with negative control, significant difference (P < 0.05)；
*, compared with negative control group, significant difference (P < 0.01)
Experimental result is shown in Table 2, as shown in Table 2, biologically active polypeptide FDPTLHQ is added in experimental group, concentration is respectively
1mg/mL and 0.5mg/mL makes an oxygen of the promotion macrophage grown under inflammatory conditions for growing under normal circumstances with LPS
Changing the nitrogen amount of inducing has facilitation.Compared with cell blank group, there is significant difference (P<0.05).Work as biologically active polypeptide
A concentration of 0.1mg/mL of addition of FDPTLHQ, compares in the case where LPS makes inflammatory conditions, also macrophage nitric oxide can be promoted to lure
The increase of raw amount, and there is significant difference (P<0.05).But compared with the cell blank group grown under normal circumstances, do not have
Significant difference.Illustrating that biologically active polypeptide FDPTLHQ has under the conditions of a certain concentration promotes macrophage nitric oxide to lure
It is raw to measure increased ability.
The activity of fighting against senium of 3 biologically active peptide of embodiment is tested
One, biologically active polypeptide FDPTLHQ improves the experiment of drosophila survival ability
1. experiment reagent and instrument：
Reagent：Oregon K wild type Drosophila melanogasters, agricultural college of Shanghai Communications University genetics experiments room；Agar powder, state
Chemical reagent Co., Ltd of medicine group；The biologically active polypeptide FDPTLHQ that embodiment 1 obtains.
Instrument and equipment：The ultra-clean water of CM-230 types mole, Shanghai Moller scientific instrument Co., Ltd；G136T type Zealway intelligence
Energy high-temperature sterilization pot, Xiamen Zhi Wei instruments Science and Technology Ltd.；BJ-CD SERIES bio-incubators, Shanghai is rich to prove to be true after interrogation industry public affairs
Department；GRX-9073 type hot air sterilizers, the permanent Science and Technology Ltd. in Shanghai one.
2. experimental method：
Using drosophila as experimental model：The drosophila adult newly to sprout wings in 8 hours is collected, divides male and female random transferring to respectively after anesthesia
In experimental group, every group of each gender 100, every group of setting 3 is parallel, and control group gives conventional corn powder culture medium, experimental group
FDPTLHQ biologically active peptides-corn culture medium respectively containing 0.05mg/ml, 0.5mg/ml, 1mg/ml.More renew within every 2 days
Fresh culture medium is primary, observes and records the death toll of different sexes drosophila daily, until drosophila is all dead.Draw drosophila
Survivorship curve, and calculate the average life span of different sexes drosophila and maximum life span (takes 5 drosophilas of last death to unite
Meter).
3. experimental result and analysis：
This experiment is as follows to the result of study of the life span of drosophila melanogaster of feeding various concentration biologically active peptide：It can be with from Fig. 4 (A)
It was found that for blank control group Male Drosophila, the FDPTLHQ of a concentration of 0.05mg/ml of feeding is not significantly changed
The survival rate of Male Drosophila, and when peptide concentration reaches 0.5mg/ml and 1mg/ml, same time point, the survival rate of Male Drosophila
It is significantly improved.From Fig. 4 (B), relative to blank control group female Drosophila, feeding a concentration of 0.5mg/ml and 1mg/ml
When, in same time point, the survival rate of female Drosophila increases, but result difference unobvious.
Influence situations of the table 3-1FDPTLHQ to the Male Drosophila service life
Note：* mark is compared with blank control group, significant difference (P<0.05)；Similarly hereinafter.
Influence situations of the table 3-2FDPTLHQ to the female Drosophila service life
From table 3-1 it is found that relative to blank control group, low dose group Male Drosophila average life span does not have significant change,
But middle dose group and advanced amount group Male Drosophila average life span are improved, and respectively 16.27% and 9.49%, but only middle dosage
Group produces significant difference (p<0.05), illustrate that the average life span conspicuousness of middle dose group Male Drosophila improves.Meanwhile middle dose
The half death time of amount group and high dose group drosophila is improved, but does not have notable difference in terms of MaLS.By table
3-2 is it is found that female Drosophila low dose group, middle dose group and high dose group increase in terms of average life span, but do not produce
Raw significant difference.But the MaLS of middle dose group and high dose group increases, and extends 7 days respectively compared with blank control group
With 6 days, and produce significant difference (P<0.05).
This is the experiment results show that biologically active polypeptide FDPTLHQ can improve the average life span of drosophila under a certain concentration
And MaLS, but it is related with concentration and gender.This phenomenon related to tested material concentration, strain may be because
FDPTLHQ participates in the part biological metabolism of drosophila, or the antioxidant system by improving drosophila tissue extends fruit to reach
The effect in fly service life.Since the metabolism of different lines drosophila can have any different, to cause the difference of result.And the difference of gender,
May be since female Drosophila is inherently with certain conservative and to the resistance of external environment, so FDPTLHQ is to female
Property life span of drosophila melanogaster extension be not obvious.
Two, biologically active polypeptide FDPTLHQ hydrogen peroxide Acute oxidative is tested
1. experiment reagent and instrument：
Reagent：Oregon K wild type Drosophila melanogasters, agricultural college of Shanghai Communications University genetics experiments room；Agar powder, state
Chemical reagent Co., Ltd of medicine group；Hydrogen peroxide, Shanghai Ling Feng chemical reagent Co., Ltd；The biology that embodiment 1 obtains is living
Property polypeptide FDPTLHQ.
Instrument and equipment：The ultra-clean water of CM-230 types mole, Shanghai Moller scientific instrument Co., Ltd；Mi Libo Millipore
MILLEX GP0.22 μm filter membranes, Millipore Corp. of the U.S.；GL-22M high speed freezing centrifuges, Shanghai Lu Xiang instrument centrifuge instruments
Co., Ltd.
2. experimental method：
The drosophila adult newly to sprout wings in 8 hours is collected, is divided after anesthesia in male and female random transferring to each experimental group, takes the service life real
The preferable peptide concentration culture medium of middle result is tested, blank control group is set and experimental group, control group give conventional corn powder culture medium.
Every group of male and female gender drosophila is 50, is cultivated three weeks drosophila.Then 5 males and 5 female Drosophilas is taken to be transferred to every time
In one new container, new container is included there are one papery disk, disk contain the sucrose solution of 300 μ L a concentration of 5% with
And a concentration of 30% hydrogen peroxide 1ml, blank group and experimental group are exposed to the toxicity peroxide that this hydrogen peroxide generates
In environment, 10 Duplicate Samples of every group of setting observe its oxidation resistance.Every 4 hour record drosophila The dead quantity and gender, until
Drosophila is all dead.
3. experimental result and analysis：
From Fig. 5 (A) as can be seen that for Male Drosophila, after FDPTLHQ feedings, in Each point in time, male fruit
The survival rate of fly is above the drosophila without FDPTLHQ feedings, and the time-to-live increases compared with blank control group, illustrates feeding
After FDPTLHQ, Male Drosophila oxidation resistance increases.In Fig. 5 (B), the female Drosophila of feeding FDPTLHQ, in high concentration
Hydrogen peroxide environment in the apparent high and control group of survival rate in 15h, illustrated female Drosophila oxidation resistance this period
It improves.But later experiments group and control group survival curve essentially coincide, and illustrate the anti-oxidant energy of the female Drosophila of feeding FDPTLHQ
Power gradually weakens, by not having difference with control group after a certain period of time.This experimental results showed that, FDPTLHQ can improve drosophila
Oxidation resistance.According to H2O2Acute toxicity testing is as a result, can speculate that FDPTLHQ may be by adjusting cat catalase
Activity improves drosophila to H2O2The resistivity of damage.
Three, the experiment that biologically active polypeptide FDPTLHQ influences drosophila SOD and MAD content
1. experiment reagent and instrument：
Reagent：Oregon K wild type Drosophila melanogasters, agricultural college of Shanghai Communications University genetics experiments room；Agar powder, state
Chemical reagent Co., Ltd of medicine group；MDA lipid peroxide kits, Science and Technology Ltd. of Nanjing Keygen Biotech；SOD super oxygens
Compound is disproportionated enzyme reagent kit, and bio tech ltd is built up in Nanjing；The biologically active polypeptide FDPTLHQ that embodiment 1 obtains.
Instrument and equipment：The ultra-clean water of CM-230 types mole, Shanghai Moller scientific instrument Co., Ltd；Organize homogenizer, Shanghai
Member is as bio tech ltd；G136T type Zealway intelligence high-temperature sterilization pots, Xiamen Zhi Wei instruments Science and Technology Ltd.；
BJ-CD SERIES bio-incubators, Shanghai Bo Xun industrial corporations；GRX-9073 type hot air sterilizers, the permanent science and technology in Shanghai one have
Limit company；Infinite type microplate reader, Austrian Di Ken Co., Ltds.
2. experimental method：
The drosophila adult newly to sprout wings in 8 hours is collected, is divided after anesthesia in male and female random transferring to each experimental group, every group each
Gender 100, every group of setting 3 is parallel, and control group gives conventional corn powder culture medium, and experimental group is respectively to contain 0.05mg/
FDPTLHQ biologically active peptides-corn culture medium of ml, 0.5mg/ml, 1mg/ml.It is primary to replace within every 2 days fresh culture, raising
After 30 days, every group weighs drosophila 40mg, adds 0.5ml physiological saline, and homogenate is ground in ice bath, and interval 10s seconds is repeated 3
It is secondary, homogenate is made, illustrates to measure every group of drosophila SOD activity and MDA levels according to kit.Utilize MDA detection kits
The levels of the lipid peroxidation product MDA in drosophila body are detected, the wavelength of spectrophotometer is 532nm.
3. experimental result and analysis：
Influences of the table 4FDPTLHQ to drosophila SOD, MDA
As can be known from Table 4, relative to blank control group, the SOD contents in the female male drosophila body of polypeptide processing group are improved,
And for Male Drosophila group, when peptide concentration reaches 1mg/ml, there is significant difference in the SOD contents in drosophila body, and
Then there is significant difference when peptide concentration is 0.5mg/ml and 1mg/ml in female Drosophila group.Illustrate by taking in certain polypeptide,
Internal SOD contents can be improved, and body protective itself is helped to prevent oxidative damage.MDA contents can see from table 4,
MDA contents in experimental group Male Drosophila and female Drosophila body have reduction.Relative to male blank control group MDA contents 1.37
There is the reduction of conspicuousness in ± 0.21 μm of ol/L, the MDA contents of a concentration of 0.5mg/ml and 1mg/ml drosophilas group, and female Drosophila
In group, when 1mg/ml peptides are handled, there is the reduction of conspicuousness in the MDA contents in drosophila body.Since MDA is body lipid peroxide
Change and generate, the reduction of content illustrates that the Antioxidant Enzymes vigor of drosophila is improved indirectly, to protect body
Histoorgan not will produce a large amount of lipid peroxide.
From experimental result as can be seen that the experimental result of SOD and MDA is mutually proved, it may be said that gelatine/biological activity polypeptide
FDPTLHQ helps to improve the vigor of the Antioxidant Enzymes in body body, so as to effectively improve the oxidation resistance of body, subtracts
Few body is stimulated by the bad factor, to reduce organism aging process, aging and sick probability, all in all, for Male Drosophila
Effect be better than female Drosophila.
The above description of the embodiments is intended to facilitate ordinary skill in the art to understand and use the invention.
Person skilled in the art obviously easily can make various modifications to these embodiments, and described herein general
Principle is applied in other embodiment without having to go through creative labor.Therefore, the present invention is not limited to the above embodiments, ability
Field technique personnel announcement according to the present invention, improvement and modification made without departing from the scope of the present invention all should be the present invention's
Within protection domain.
Sequence table
<110>The Shanghai bio tech ltd Bo Hui；Zhejiang Hui Tai life and healths Science and Technology Ltd.
<120>A kind of biologically active polypeptide FDPTLHQ and its preparation method and application
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 7
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 1
Phe Asp Pro Thr Leu His Gln
1 5
<210> 2
<211> 21
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
atttgatccg acattgcatc a 21
<210> 3
<211> 205
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 3
Val Ser Lys Glu Lys Phe Pro Ser Glu Lys Asn Leu Asp Glu Lys Glu
1 5 10 15
Thr Ala Ser Thr Pro Glu Ala Ala Lys Lys Lys Val Thr Glu Asp Lys
20 25 30
Lys Ala Lys Lys Asp Lys Glu Ala Lys Lys Asp Lys Glu Ala Lys Lys
35 40 45
Asp Asn His Asp Glu Lys Leu Ala Lys Glu Ile Ala Asp Leu Lys Asp
50 55 60
Lys Asn Lys Glu Leu Glu Asp Lys Tyr Leu Arg Ser Glu Ala Glu Ile
65 70 75 80
Gln Asn Met Gln Asn Arg Tyr Ser Lys Glu Arg Ala Gln Leu Ile Lys
85 90 95
Tyr Glu Ser Gln Ser Leu Ala Lys Asp Ile Leu Pro Ala Val Asp Asn
100 105 110
Leu Glu Arg Ala Leu Ser Val Glu Ala Asp Asp Asp Val Ser Lys Gln
115 120 125
Leu Lys Lys Gly Val Lys Met Thr Leu Asp Ser Leu Thr Lys Ala Leu
130 135 140
Lys Asp His Gly Ile Val Glu Ile Glu Ala Glu Asp Val Lys Phe Asp
145 150 155 160
Pro Thr Leu His Gln Ala Val Gln Thr Val Val Ala Glu Asn Asp Asp
165 170 175
Gln Lys Asp His Val Val Gln Val Leu Gln Lys Gly Tyr Gln Tyr Lys
180 185 190
Asp Arg Thr Leu Arg Pro Ala Met Val Val Val Ala Gln
195 200 205
Claims (10)
1. a kind of biologically active polypeptide FDPTLHQ, which is characterized in that its amino acid sequence is Phe-Asp-Pro-Thr-Leu-
His-Gln。
2. a kind of biologically active polypeptide FDPTLHQ according to claim 1, which is characterized in that the biologically active polypeptide
From Lactobacillus helveticus mycoprotein.
3. encoding the nucleotide fragments of biologically active polypeptide FDPTLHQ described in claim 1, which is characterized in that the nucleotide
The sequence of segment such as SEQ ID NO：Shown in 2.
4. the preparation method of biologically active polypeptide FDPTLHQ as described in claim 1, which is characterized in that pass through genetic engineering
Method is artificial synthesized or Lactobacillus helveticus thalline is directly obtained by the method that clasmatosis isolates and purifies, or directly passing through
Be synthetically prepared.
5. the application of biologically active polypeptide FDPTLHQ as described in claim 1, which is characterized in that the biologically active polypeptide
Applications of the FDPTLHQ in preparing the food with anti-inflammatory properties, health products, drug or cosmetics.
6. the application of biologically active polypeptide FDPTLHQ as described in claim 1, which is characterized in that the biologically active polypeptide
Applications of the FDPTLHQ in preparing the food with anti-senescence function, health products or drug.
7. the application of biologically active polypeptide FDPTLHQ as described in claim 1, which is characterized in that the biologically active polypeptide
Applications of the FDPTLHQ in preparing the food with anti-inflammatory properties and anti-senescence function, health products or drug.
8. a kind of anti-inflammatory products, which is characterized in that including biologically active polypeptide FDPTLHQ or described lifes as described in claim 1
The derivative of object active peptides FDPTLHQ；The anti-inflammatory products include anti-inflammatory food, anti-inflammatory health product, anti-inflammatory drug or anti-
Scorching cosmetics；The derivative of the biologically active polypeptide FDPTLHQ refers in the amino acid side of biologically active polypeptide FDPTLHQ
On chain group, aminoterminal or c-terminus carry out hydroxylating, carboxylated, be carbonylated, methylate, acetylation, phosphorylation, esterification or sugar
Baseization is modified, obtained polypeptide derivative.
9. a kind of anti-aging product, which is characterized in that including biologically active polypeptide FDPTLHQ or described as described in claim 1
The derivative of biologically active polypeptide FDPTLHQ；The anti-aging product includes antisenility cistanche food, antisenescence health product or anti-ageing
Old drug；The derivative of the biologically active polypeptide FDPTLHQ refers to the amino acid side chain in biologically active polypeptide FDPTLHQ
On group, aminoterminal or c-terminus carry out hydroxylating, carboxylated, be carbonylated, methylate, acetylation, phosphorylation, esterification or glycosyl
Change modification, obtained polypeptide derivative.
10. a kind of product with anti-inflammatory properties and anti-senescence function, which is characterized in that including biology as described in claim 1
The derivative of active peptides FDPTLHQ or described biologically active polypeptides FDPTLHQ；Production with anti-inflammatory properties and anti-senescence function
Product include food, health products or drug；The derivative of the biologically active polypeptide FDPTLHQ, refers in biologically active polypeptide
On the amino acid side groups of FDPTLHQ, aminoterminal or c-terminus progress hydroxylating, carboxylated, it is carbonylated, methylates, acetyl
Change, phosphorylation, esterification or glycosylation modified, obtained polypeptide derivative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810711974.9A CN108794588B (en) | 2018-06-29 | 2018-06-29 | Bioactive polypeptide FDPTLHQ and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810711974.9A CN108794588B (en) | 2018-06-29 | 2018-06-29 | Bioactive polypeptide FDPTLHQ and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108794588A true CN108794588A (en) | 2018-11-13 |
| CN108794588B CN108794588B (en) | 2020-01-21 |
Family
ID=64073239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810711974.9A Active CN108794588B (en) | 2018-06-29 | 2018-06-29 | Bioactive polypeptide FDPTLHQ and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108794588B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116836233A (en) * | 2023-08-31 | 2023-10-03 | 中国农业大学 | Anti-inflammatory active polypeptide and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009121176A1 (en) * | 2008-03-31 | 2009-10-08 | The University Of British Columbia | Insulin-induced gene (insig) peptide compositions and methods for cytoprotection |
| CN105254750A (en) * | 2015-10-16 | 2016-01-20 | 上海交通大学 | Bioactive polypeptide FGYSGAFKCL as well as preparation and application thereof |
-
2018
- 2018-06-29 CN CN201810711974.9A patent/CN108794588B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009121176A1 (en) * | 2008-03-31 | 2009-10-08 | The University Of British Columbia | Insulin-induced gene (insig) peptide compositions and methods for cytoprotection |
| CN105254750A (en) * | 2015-10-16 | 2016-01-20 | 上海交通大学 | Bioactive polypeptide FGYSGAFKCL as well as preparation and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| JIEHUI,ZHOU 等: "Immunomodulating effects of casein-derived peptides QEPVL and QEPV on lymphocytes in vitro and in vivo", 《FOOD & FUNCTION》 * |
| 钱蕙佶等: "瑞士乳杆菌胞内生物活性肽的分离鉴定", 《中国乳品工业》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116836233A (en) * | 2023-08-31 | 2023-10-03 | 中国农业大学 | Anti-inflammatory active polypeptide and application thereof |
| CN116836233B (en) * | 2023-08-31 | 2023-11-14 | 中国农业大学 | Anti-inflammatory active polypeptide and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108794588B (en) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108794598B (en) | Bioactive polypeptide NARIQDNLYLAV, and preparation method and application thereof | |
| CN107236031A (en) | A kind of biologically active polypeptide PMIGVNQELAY and its preparation method and application | |
| CN108794593A (en) | A kind of biologically active polypeptide GSVNDVQ and its preparation method and application | |
| CN107759681A (en) | A kind of biologically active polypeptide INNQFLPYPYYAKPA and its preparation method and application | |
| CN108997483B (en) | Bioactive polypeptide DQDLVLI and preparation method and application thereof | |
| CN108017701A (en) | A kind of biologically active polypeptide FPKYPVEPF and its preparation method and application | |
| CN107840880A (en) | A kind of biologically active polypeptide GLNYYQQKPVA and its preparation method and application | |
| CN108794590A (en) | A kind of biologically active polypeptide EPGIVNLD and its preparation method and application | |
| CN107814839A (en) | A kind of biologically active polypeptide PIGSENSEKTTMPL and its preparation method and application | |
| CN108341855A (en) | A kind of biologically active polypeptide ADVKIGNDTVIEGN and its preparation method and application | |
| CN108558991A (en) | A kind of biologically active polypeptide GIQDPKEP and its preparation method and application | |
| CN108794605B (en) | Bioactive polypeptide SRPETSG, and preparation method and application thereof | |
| CN108794588A (en) | A kind of biologically active polypeptide FDPTLHQ and its preparation method and application | |
| CN108794603A (en) | A kind of biologically active polypeptide TVTMLMTTIL and its preparation method and application | |
| CN108794595A (en) | A kind of biologically active polypeptide IYQMVHA and its preparation method and application | |
| CN107880107B (en) | Bioactive polypeptide QVLSNTVPA, and preparation method and application thereof | |
| CN107759680A (en) | A kind of biologically active polypeptide IPNPIGSENSGKTT and its preparation method and application | |
| CN108034002A (en) | A kind of biologically active polypeptide PEVIESPPEINTV and its preparation method and application | |
| CN108794604B (en) | Bioactive polypeptide SVAPAAAGIN, and preparation method and application thereof | |
| CN107814836A (en) | A kind of biologically active polypeptide FPGPIPNS and its preparation method and application | |
| CN108794594A (en) | A kind of biologically active polypeptide IPLIAGS and its preparation method and application | |
| CN107880108A (en) | A kind of biologically active polypeptide SFSDIPNPIGSE and its preparation method and application | |
| CN108794592A (en) | A kind of biologically active polypeptide NAGVLQDIRFKQ and its preparation method and application | |
| CN108794591A (en) | A kind of biologically active polypeptide GGEPFLN and its preparation method and application | |
| CN107814843A (en) | A kind of biologically active polypeptide VMFPPQ and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |